{"id":84307,"date":"2018-01-10T15:53:13","date_gmt":"2018-01-10T13:53:13","guid":{"rendered":"https:\/\/www.technion.ac.il\/blog\/biomedical-informatics-at-technion\/"},"modified":"2018-01-10T15:53:13","modified_gmt":"2018-01-10T13:53:13","slug":"biomedical-informatics-at-technion","status":"publish","type":"post","link":"https:\/\/www.technion.ac.il\/en\/blog\/biomedical-informatics-at-technion\/","title":{"rendered":"Biomedical Informatics at Technion"},"content":{"rendered":"

Big Step for the Future of Medicine: Biomedical Informatics Conference at the Technion<\/b><\/span><\/p>\n

At the international conference, experts discussed the use of Big Data and deep learning in numerous fields related to development of \u201cprecision medicine\u201d<\/b><\/span><\/p>\n

On December 13-14, the Technion-Israel Institute of Technology hosted the first international conference on biomedical informatics \u2013 a field based on computerized analysis of the overall data amassed by academia, hospitals and health funds. The use of deep learning, Big Data and other technologies gives experts the ability to analyze information in an intelligent, rapid and efficient manner. The goal is to <\/span>precisely adapt treatments to specific patients<\/b>.<\/span><\/p>\n

Technion President <\/span>Prof. Peretz Lavie<\/b> congratulated the organizers, Dr. Kira Radinsky and Prof. Roy Kishony, Director of the Technion\u2019s Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering. \u201cWe\u2019re living in a fascinating era for scientific research, an era where extensive data is used to improve diagnoses and treatment. There is no doubt that Israel in general, and the Technion in particular, is an excellent location for such a pioneering conference, since the Technion is one of the only technological institutions in the world with its own medical school. Our cooperation with China, where the Guangdong Technion Israel Institute of Technology was recently inaugurated, opens us to a goldmine of data.\u201d \u00a0<\/span><\/p>\n

Serial entrepreneur <\/span>Jonathan Adiri<\/b> gave a keynote lecture about \u201cThe Era of Permanent Revolution.\u201d Adiri was Pres. Shimon Peres\u2019s Chief Technology Adviser, a position that enabled him to build ties in the U.S. and Korea. He was president of the inaugural class of Singularity University (2009), which was founded by NASA and Google, and is the founder of Healthy.io, a medical diagnostics company based on the use of Smartphone cameras, that was recently mentioned in <\/span>The Economist<\/span><\/i>.<\/span><\/p>\n

Adiri described the challenges that will be encountered by tech companies in the near future, when Smartphones will be used for inexpensively and quickly diagnosing diseases. \u201cWe are in the midst of a time of perpetual revolution,\u201d he said. \u201cInnovation revolutions don\u2019t happen if they aren\u2019t economically beneficial. For example, the drone market experienced a drastic plunge in prices \u2013 parts that cost $100 in 2007 now cost 50 cents. The computing power of the iPhone 4, which currently costs hundreds of dollars, is stronger than the computing power of the first mission to the moon. The success of reusable space launchers is so huge because of the economic considerations: these launchers save enormous amounts of money. Imagine that every time an airplane lands after a flight, it would be destroyed \u2013 this was the situation with previous space launchers. Israel is very well positioned for this era, for shaping the future and spreading knowledge, thanks to an efficient and decentralized system of decision making.\u201d <\/span><\/p>\n

Hanna Bayer<\/b>, the Chief Scientist of New York University\u2019s HUMAN project , which will be launched in 2018 in New York City \u00a0presented the project \u00a0that will collect information from approximately 10,000 people from all five boroughs for a period of 20 years. The data will be collected on a single research platform and will be used by researchers from all over the world for analyzing data connected to health, education, genetics, the environment and lifestyle. The aim is to identify the links between different variables using Big Data technology. According to Bayer, \u201cinstead of looking for specific data and connecting them to a person\u2019s health, we will continuously monitor a large spectrum of data related to a person\u2019s biology, genetics, behavior, environment, food intake and exercise regimen, as well as what he buys and with whom he meets. The idea is to measure everything that can be measured, based on a large sample and over a long period of time, in order to reach conclusions that can be implemented and will help improve human health.\u201d \u00a0<\/span><\/p>\n

Dr. Ran Balicer<\/b>, Director of the Clalit Research Institute in Israel, spoke about the future challenges in medicine from the point of view of the service provider. \u201cHealth funds and hospitals are contending with several large challenges simultaneously: the aging of the population, the large number of diseases and harsh budget restrictions. A considerable part of the solution to these challenges lies in technology. Technology can help us prevent medical errors, which is the third most common cause of death in the world \u2013 before accidents, diabetes, drugs, etc. \u2013 by preventing unnecessary (or harmful) interventions, which currently account for about one-third of all medical procedures, and by carrying out procedures not currently done today. Clalit Health Services, which is responsible for 53% of people insured by Israel\u2019s health funds, provides hospital care in addition to community medical services. We have accrued an enormous amount of data, and our goal is to harness this information for the good of the patient. We will do so through proactive medicine that invites the patient to carry out critical tests before he feels that there is a problem and before the symptoms appear. We have had several successes in predicting diseases and adapting treatment to specific patients, and we do everything in order to improve our use of technology for the patient\u2019s benefit.\u201d \u00a0<\/span><\/p>\n

Dr. Varda Shalev<\/b>, Director of Maccabi Health Care Services\u2019 Institute for Research and Innovation, said that \u201cin the past, the medical staff wanted information. Today, there is plenty of information and what they\u2019re lacking is the tools to analyze the information. Maccabi has approximately two million members \u2013 a relatively large and stable cohort \u2013 and all tests are carried out in a single lab. That\u2019s an excellent base for using innovative technology to analyze data, and we are expending a great deal of effort to do so in the most effective ways. One example is our cooperation with the organizer of today\u2019s conference, Prof. Kishony, analyzing urine tests carried out all over Israel.\u201d <\/span><\/p>\n

Conference organizers: Dr. Kira Radinsky and Prof. Roy Kishony of the Technion\u2019s Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering<\/span><\/p>\n

Dr. Kira Radinsky<\/b>, who began studying at the Technion\u2019s Computer Science Faculty at the age of 15, completed three degrees at the Faculty: a B.Sc. as part of the Rothschild Scholars Program for Excellence, and a Masters and Ph.D. under the supervision of Prof. Shaul Markovitch. Already while pursuing her Masters degree, Dr. Radinsky developed a metahodology for predicting future events based on Internet queries. Based on this methodology, she founded the company SalesPredict, which was eventually acquired by eBay. Companies hire SalesPredict to forecast the probability of selling products to other companies, and following its acquisition, Dr. Radinsky was appointed eBay\u2019s Chief Scientist in Israel. She is currently a guest professor at the Technion. <\/span><\/p>\n

At the conference, Dr. Radinsky\u2019s lecture presented possible ways to harness deep learning and big data for identifying various causal links related to medicine. \u201cRather that looking for specific links based on our hypotheses, we can let the computer find such links without guidance, based on a huge sample set. For example, in this way we were able to find unknown side effects of medicines and combinations of medicines. I believe that in the future we will not only be able to examine the effects of combining medicines but also develop new medicines in this manner. It\u2019s important to point out that this is a completely new type of science that isn\u2019t based on experiments that test hypotheses but, rather, on data that determine the research\u2019s hypothesis.\u201d<\/span><\/p>\n

Prof. Roy Kishony<\/b> is the head of the Lorry Lokey Interdisciplinary Center for Life Sciences and Engineering at the Technion and a faculty member of both the Technion\u2019s Biology and Computer Science departments. In 2016, Prof. Kishony published an article in the journal \u2018Science\u2019 where he presented an innovative platform that makes it possible to precisely track bacteria\u2019s evolution while they are developing resistance to antibiotics. This platform was the first demonstration of its kind showing the connection between genetic adaptation and spatial constraints.\u00a0<\/span><\/p>\n

Prof. Kishony\u2019s lecture at the conference discussed the necessary processes given the fear of a post-antibiotic era when bacteria won\u2019t react anymore to antibiotic drugs. \u201cWe must not only know the bacteria\u2019s current resilience level, but also which resilience level they are expected to develop, and maybe initiate a reverse process that will prompt them to develop renewed sensitivity to the drug. This is \u2018anticipatory medicine\u2019 that will give us ways to diagnose the disease before its outbreak \u2013 a diagnosis that will make it possible to predict the future and create a treatment that is better adapted to the patient.\u201d <\/span><\/p>\n

The students Lindsay Moore and Idan Yelin were the winners of the scientific posters competition that took place at the conference. <\/b>Lindsay Moore poster presented the Alignment of Single-cell based development trajectories, and Idan Yelin poster presented Genomic proof of probiotic transmission from capsule to blood in patients with <\/span>Lactobacillus Rhamnosus<\/span><\/i> GG Bacteremia.<\/span><\/p>\n

.<\/span><\/p>\n